Southeastern Research Center | Winston-Salem, NC
Status and phase
Conditions
Treatments
About
The purpose of this study is to evaluate the safety and tolerability of 72 milligrams per kilogram (mg/kg) and 180 mg/kg Alpha-1 15%, administered as a single-dose subcutaneous (SC) infusion and subsequently as weekly SC infusions over 8 weeks in participants with Alpha1-Antitrypsin Deficiency (AATD).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
16 participants in 6 patient groups
Loading...
Central trial contact
Beatriz Garcia Castro; Elsa Mondou
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal